Drug Profile
Disodium edetate/ethyl alcohol/minocycline - Citius Pharmaceuticals
Alternative Names: Alcohol/edetate-disodium/minocycline; Alcohol/minocycline/disodium-edetate; Alcohol/minocycline/edetate-disodium; Disodium-edetate/alcohol/minocycline; Disodium-edetate/ethanol/minocycline; Disodium-edetate/minocycline/alcohol; Disodium-edetate/minocycline/ethanol; Edetate-disodium/alcohol/minocycline; Edetate-disodium/ethanol/minocycline; Edetate-disodium/minocycline/alcohol; Edetate-disodium/minocycline/ethanol; Mino-Lok; Mino-Lok Therapy (MLT); Minocycline-EDTA-EtOH; Minocycline/alcohol/disodium-edetate; Minocycline/alcohol/edetate-disodium; Minocycline/disodium-edetate/alcohol; Minocycline/disodium-edetate/ethanol; Minocycline/edetate-disodium/alcohol; Minocycline/edetate-disodium/ethanol; Minocycline/ethanol/disodium-edetate; Minocycline/ethanol/edetate-disodium; MinoLokLatest Information Update: 04 Jan 2024
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Citius Pharmaceuticals Inc; Leonard Meron Biosciences; University of Texas M. D. Anderson Cancer Center
- Class Alcohols; Anti-infectives; Antibacterials; Anticoagulants; Antiseptics; Disinfectants; Small molecules; Tetracyclines
- Mechanism of Action Chelating agents; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Catheter infections
Most Recent Events
- 01 Dec 2023 Leonard-Meron Biosciences completes enrolment in a phase-III trial in Catheter infections (In children, In the elderly, In adults, Adjunctive therapy) in USA, India and Puerto Rico (unspecified route) (NCT02901717)
- 10 Feb 2023 Phase-III clinical trials in Catheter infections (In children, In adults, In the elderly) in India
- 07 Dec 2022 Phase-III development is ongoing Puerto Rico (NCT02901717)